IFNA1 and coronary artery disorder: When Bulevirtide and Peg-IFN-α are administered in combination for 48 weeks, 80.0% of CHD patients had undetectable HDV RNA, and after an additional 24 weeks of treatment-free follow-up, still, 53.3% of CHD patients had undetectable HDV RNA.